GLP-1 Weight-Loss Drugs May Shield Heart Microvessels After Heart Attacks
TL;DR Summary
A Bristol/UCL study suggests GLP-1 weight-loss meds like semaglutide and liraglutide may protect heart tissue after a heart attack by relaxing pericytes and widening microvessels to prevent ‘no-reflow’—a finding from animal studies that hints at repurposing these drugs for post-infarct cardioprotection, though human trials are needed.
- Weight Loss Drugs Like Ozempic and Wegovy Show Surprising Heart Health Benefits SciTechDaily
- The Many Cardiovascular Benefits of GLP-1 Drugs Medscape
- Diabetes: GLP-1s and Healthy Lifestyle Help Lower Cardiovascular Risk Healthline
- Weight-loss drugs could prevent fatal complications from heart attacks, UK study finds The Guardian
- Healthy lifestyle habits lower CV risk in type 2 diabetes, regardless of GLP-1 use Healio
Reading Insights
Total Reads
0
Unique Readers
3
Time Saved
7 min
vs 8 min read
Condensed
97%
1,497 → 46 words
Want the full story? Read the original article
Read on SciTechDaily